Carr Financial Group’s Akebia Therapeutics AKBA Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
– Sell
-15,581
Closed -$17.8K – 186
2026
Q2
$17.8K Hold
15,581
– – ﹤0.01% 182
2026
Q1
$21.7K Buy
15,581
+4,000
+35% +$5.5K 0.01% 174
2025
Q4
$18.6K Buy
+11,581
New +$24.2K 0.01% 186

Other funds holding AKBA

Carr Financial Group's AKBA Position: Q3 2026 in Review

Carr Financial Group sold out of Akebia Therapeutics (AKBA) in Q3 2026, closing a stake of 15,581 shares — an estimated $17.8K sold.

Carr Financial Group first reported a position in AKBA in Q4 2025 and held it in 3 quarters. The position peaked at $21.7K in Q1 2026. 127 funds tracked by Wall St. Rank hold AKBA as of Q3 2026.

  • Carr Financial Group reported no remaining Akebia Therapeutics position as of Q3 2026 after selling out during the quarter.
  • Carr Financial Group sold 15,581 Akebia Therapeutics shares in Q3 2026, an estimated $17.8K.
  • Carr Financial Group first reported a position in Akebia Therapeutics in Q4 2025 and held it in 3 quarters.
  • Carr Financial Group's Akebia Therapeutics position peaked at $21.7K in Q1 2026.
  • 127 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2026.

Based on Carr Financial Group's 13F filing for Q3 2026, filed 10 Nov 2026.